# Antiverse

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/antiverse

- Industry: Biotechnology
- Headquarters: Cardiff, UK
- Website: www.antiverse.io/
- Total disclosed funding: $19M
- Latest round: Series A (Mar 3, 2026)
- Investors on record: 13

## About

Antiverse Ltd, based in the UK, specializes in innovative antibody design, utilizing advanced machine learning and engineering techniques to create therapeutics targeting complex drug targets. Founded in 2017 in Wales, UK, Antiverse Ltd focuses on developing target-specific antibody libraries. The company has evolved its strategies to enhance its capabilities in drug discovery, specifically addressing G-protein coupled receptors and ion channels. The company operates independently and was established by founder Ben H. Antiverse has successfully completed 7 deals with its most recent funding round in May 2024, raising GBP 5.557 million in SEED funding from investors including AngelHub Limited, Innospark Ventures, Kadmos Capital, Tensor Ventures, and the UK Innovation & Science Seed Fund. This funding has brought the total amount raised to GBP 5.557 million and the current company valuation to GBP 8.081 million.Antiverse specializes in the design of target-specific antibody libraries engineered to address complex drug targets, particularly G-protein coupled receptors and ion channels. By employing advanced machine learning techniques alongside cutting-edge cell line engineering, Antiverse creates innovative de novo antibody therapeutics. The company aims to enhance the efficiency of the antibody discovery process, enabling clients to identify functional binders within a six-month timeframe. Its primary clients are global pharmaceutical companies, particularly in North America and Europe, where the demand for advanced therapeutic solutions is significant.Antiverse generates revenue through strategic partnerships and collaborations with leading pharmaceutical companies. The business model primarily involves B2B transactions structured around tailored programs to meet specific client needs. It earns revenue from the provision of antibody design services, which encompass various phases of drug development including custom antibody libraries and validation processes. Antiverse engages in project-based contracts with clients, negotiating based on the complexity of specific projects, focusing on delivering scientifically driven results. In February 2026, Antiverse Ltd raised USD 9.3 million in series A funding led by Soulmates Ventures, with participation from Innovation Investment Capital, DOMiNO Ventures, Development Bank of Wales, Kadmos Capital, and i&i Bio. The company will use the March 2026 funding to support its growth and further development of its AI-powered antibody discovery platform.

## Funding rounds

- Series A, Mar 3, 2026, $9.3M — Development Bank of Wales, i&i Bio, DOMiNO Ventures, Kadmos Capital, Soulmates Ventures
- Seed, May 31, 2024, $7.1M — Innospark Ventures, UK Innovation & Science Seed Fund, AngelHub Limited, Tensor Ventures, i&i Bio, Kadmos Capital
- Seed, Mar 15, 2021, $1.9M — Cambridge Angels Group, Development Bank of Wales, ACF Investors, Wren Capital, SyndicateRoom, UK Innovation & Science Seed Fund, Tensor Ventures
- Seed, Aug 8, 2018, $0.3M — UK Innovation & Science Seed Fund

## Investors

- UK Innovation & Science Seed Fund (https://capitalatlas.ai/funds/uk-innovation-science-seed-fund) — Seed
- Cambridge Angels Group — Seed
- Development Bank of Wales (https://capitalatlas.ai/funds/development-bank-of-wales) — Seed, Series A
- ACF Investors (https://capitalatlas.ai/funds/acf-investors) — Seed
- Wren Capital (https://capitalatlas.ai/funds/wren-capital) — Seed
- SyndicateRoom (https://capitalatlas.ai/funds/syndicateroom) — Seed
- Tensor Ventures (https://capitalatlas.ai/funds/tensor-ventures) — Seed
- Innospark Ventures (https://capitalatlas.ai/funds/innospark-ventures) — Seed
- AngelHub Limited — Seed
- i&i Bio (https://capitalatlas.ai/funds/i-i-bio) — Seed, Series A
- Kadmos Capital (https://capitalatlas.ai/funds/kadmos-capital) — Seed, Series A
- DOMiNO Ventures (https://capitalatlas.ai/funds/domino-ventures) — Series A
- Soulmates Ventures (https://capitalatlas.ai/funds/soulmates-ventures) — Series A